ľ��ֱ��

News Release

Tuesday, January 9, 2024

A common marker of neurological diseases may play role in healthy brains

NIH-funded research could change how we think about the causes of disorders like Parkinson’s.

Artist’s rendering of a synapse showing phosphorylated α-synuclein in pink “gluing” synaptic vesicles together. Credit Roy Lab, UCSD

Researchers have discovered that a protein called phosphorylated α-synuclein, which is associated with several neurodegenerative diseases such as Parkinson’s disease and Lewy body dementia, is also involved in the normal processes of how neurons communicate with each other in a healthy brain. The research, published in Neuron, was funded in part by the National Institute of Neurological Disorders and Stroke (NINDS), a part of the ľ��ֱ��.   

Phosphorylation is a process where a phosphate ion is added to a specific amino acid, or building block, of a protein, in this case the protein α-synuclein. This addition can change the shape of that protein, causing it to change its level of activity. Most studies of phosphorylated α-synuclein have studied its role in certain neurological disorders such as and , where it builds up in protein clumps called Lewy bodies. These clumps are thought to be toxic to neurons, and one of the prevailing hypotheses is that the phosphorylation of the protein α-synuclein triggers these diseases.

“In most studies to date, the mere presence of α-synuclein phosphorylation is assumed to be a marker for pathology for certain disorders, like Parkinson’s and Lewy Body dementias,” said Beth-Anne Sieber, Ph.D., program director, NINDS. “Recently, there has been considerable interest in developing drugs that prevent α-synuclein phosphorylation as a way of treating these disorders. These findings challenge the current hypotheses about how these disorders may originate in the brain and may give insight into how we might better treat them.”

Previous work by the lab of Subhojit Roy, M.D., Ph.D., professor at the University of California, San Diego, and senior author of the study, suggested that in a healthy brain, the α-synuclein protein tones down excessive neuronal firing to regulate neuronal communication. While exploring this theory, Roy’s group unexpectedly found that phosphorylation was necessary for the normal function of α-synuclein.  

Using a molecular modeling strategy to look at the structure of α-synuclein, Roy and his colleagues led by postdoctoral researcher Leonardo Parra-Rivas, Ph.D. discovered that when α-synuclein is phosphorylated, its structure changes in a way that promotes interactions with other proteins in healthy brains. Furthermore, they observed an association between increasing neural activity electrically or chemically and an increase in the amount of phosphorylated α-synuclein in both cultured cells and in mouse brain tissue. This finding suggests there might be a relationship between synaptic activity and α-synuclein phosphorylation.

Additionally, experiments show phosphorylation is necessary for α-synuclein to play its role in assembling a network of proteins that bind up synaptic vesicles—pockets that release chemicals enabling neurons to communicate with one another and other cells—and to slow neuronal activity. Therefore, phosphorylated α-synuclein acts almost as a brake or clutch mechanism to keep activity in certain neuronal circuits in check, suggesting that it might have a role in healthy brains, which had not previously been investigated.

“In hindsight, we hadn’t been looking at synuclein phosphorylation the right way,” said Roy. “Take for instance the circuits in the olfactory bulb, which according to our data has high levels of phosphorylated α-synuclein. The nose never stops smelling, so it needs to be active all the time. One hypothesis is that synuclein phosphorylation may have evolved as a safety mechanism to protect neuronal circuits that need to be hyperactive.”

The constant presence of α-synuclein phosphorylation in certain brain regions might reflect a need for this biochemical state in those areas. Additional studies are needed to understand how relatively low-frequency events in a healthy brain, when accumulated over a lifetime, can trigger the pathological accumulation of α-synuclein into Lewy bodies, leading to Parkinson’s disease and Lewy body dementias. Furthermore, therapies designed to block the phosphorylation of α-synuclein itself may need to consider the unintended adverse consequences of blocking a process that may help keep neurons functional during peak activity periods.

This work was funded by NINDS (NS111978, NS047101), the Farmer Family Foundation, Aligning Science Across Parkinson’s, and the Michael J. Fox Foundation for Parkinson’s Research.

This press release describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose, and treat disease. Science is an unpredictable and incremental process — each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge of fundamental basic research.

 is the nation’s leading funder of research on the brain and nervous system. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the ľ��ֱ�� (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health^®

###